Ireland
--:--IST
Recruiting Not applicable

Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children

NCT07553247 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-06-25
Last updated
2026-04-30

Condition(s) studied

Supraglottic Airway DevicesLaryseal Clear Laryngeal Mask

Investigational drug(s) / intervention(s)

LarySeal clear GroupAmbu Aura40 Group

LarySeal clear Group: Patient's airway will be secured with the LarySeal laryngeal mask. Selection of the LMA size will be based on the body weight of the patient (Bennett et al., 1996). The device will be lubricated by a water-based jelly before placement. The head of the patient will be placed in the dorsiflexion sniffing position and a lubricated LMA of appropriate size (LarySeal, Flexicare medical Ltd., UK) will be inserted using the index finger digital method technique according to manufacturers guideline. To ensure optimal inflation of SGAD cuff, it will be inflated with a volume of air according to the manufacturer's guidance (7 ml for size 1.5, 10 ml for size 2, 14 ml for size 2.5, and 20 ml for size 3).

Ambu Aura40 Group: Patient's airway will be secured with the Ambu Aura40 laryngeal mask.Selection of the LMA size will be based on the body weight of the patient. The device will be lubricated by a water-based jelly before placement. Patient's head will be in neutral position, a lubricated Ambu® Aura40(Ambu A/S, Copenhagen, Denmark) of appropriate size will be inserted using the non rotational midline approach according to manufacturer's guideline. To ensure optimal inflation of SGAD cuff, it will be inflated with a volume of air according to the manufacturer's guidance (7 ml for size 1.5, 10 ml for size 2, 14 ml for size 2.5, and 20 ml for size 3).

Study summary

Preschool children have specific anatomical and physiological characteristics which necessitates careful selection of an appropriate airway management device. Supraglottic airway devices can be used in anticipated or unanticipated difficult airway providing continuous oxygenation and ventilation with less hemodynamic stress response and less postoperative complications. So alternative techniques such as SADs have gained prominence in pediatric anesthesia both as primary airway and as a conduit for endotracheal intubation. So this study will evaluate the clinical performance of Laryseal Clear and Ambu Aura40 laryngeal mask airway in preschool children undergoing surgical procedures.

Eligibility

Sex
ALL
Min age
3 Years
Max age
6 Years
Healthy volunteers
No
Inclusion Criteria: * Consent of patient's parents or guardians of the first degree. * American Society of Anesthesiologists (ASA) Class I or II. * BMI: 5-85% of the children of the same age and sex. * Patients with mallampati grade I, II * Type of anesthesia: general anesthesia expected to last for less than 2 hours. Exclusion Criteria: * Emergency surgeries. * Expected difficult airway. * Patients with congenital or acquired airway malformations. * Patients with active upper respiratory tract infection at the time of surgery. * Patients with history of gastroesophageal reflux disease (GERD). * Patients with neuromuscular disorders affecting airway tone or respiratory function.

Primary outcome measure(s)

  • Oropharyngeal Leak Pressure (OPLP) measurement: — after device insertion , 10 minutes later
    The expiratory valve will be closed at 3L/min fresh gas flow and setting the upper pressure limit to 30 cmH2O , and the OPLP will be recorded as the peak airway pressure at which an audible gas leak occurs ( detected by auscultation over the neck just lateral to the thyroid cartilage). Head position will remain unchanged throughout the measurement to avoid variations in OPLP.

Trial sites (1)

FacilityCityRegionStatus
Zagazig university hospitals Zagazig Sharqia Province Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07553247 on ClinicalTrials.gov ↗ ← All trials in Egypt